{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:51:45Z","timestamp":1788274305199,"version":"build-2803163510"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dana PNBP Fakuktas Kedokteran Universitas Andalas","award":["38\/UN.16.02\/Fd\/PT.01.03\/2022"],"award-info":[{"award-number":["38\/UN.16.02\/Fd\/PT.01.03\/2022"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>A study of tumor resectability in pre-operative patients with advanced epithelial ovarian cancer is required to predict primary surgical benefits accurately. This study aims to investigate IL6, CA-125 and HE4 to predict tumor resectability in the pre-operative patients with advanced epithelial ovarian cancer.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This cross-sectional study was conducted in the polyclinic, oncology and gynecology inpatient room of Dr. M. Jamil Padang Hospital from June until December 2022. Advanced epithelial ovarian cancer stage based on histology result from FIGO stages IIIB\u2013IVA. IL6, CA-125, and HE4 were measured using ECLIA (electrochemiluminescence immunoassay). Categorical data were assessed using Chi-square and Mann-Whitney tests. Numerical variable correlations were analyzed using Pearson Correlation tests. While the correlation between numerical and nominal variables was analyzed using the Eta correlation test. A p-value of &lt;0,05 was considered a significant correlation. The cut-off value of serum IL6, CA-125, and HE4 was determined with a ROC curve. The sensitivity and specificity of each clinical parameter were calculated.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>There was a significant difference in IL-6 (1328 vs 752 pg\/ml; p&lt;0,001), CA-125 (1260,5 vs 819,5 U\/ml; p&lt;0,001), and HE4 levels (1320 vs 760 pmol\/L; p&lt;0,001) between patients with tumor resectability of &gt; 1 cm (suboptimal) vs &lt; 1 cm (optimal). There was a correlation between IL6 (r = 0,832), CA-125 (r = 0,716), and HE4 (r = 0,716) with tumor resectability.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Measuring IL6, CA-125, and HE4 levels is useful for clinicians to predict tumor resectability in pre-operative patients with advanced epithelial ovarian cancer.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0292282","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T17:33:31Z","timestamp":1696440811000},"page":"e0292282","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Role of Interleukin 6 (IL6), Cancer Antigen\u2014125 (CA-125), and Human Epididymis Protein 4 (HE4) to predict tumor resectability in the advanced epithelial ovarian cancer patients"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5639-3976","authenticated-orcid":true,"given":"Syamel","family":"Muhammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyhan Julio","family":"Azwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5127-4365","authenticated-orcid":true,"given":"Rauza Sukma","family":"Rita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Restu","family":"Susanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4799-7202","authenticated-orcid":true,"family":"Yusrawati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"issue":"4","key":"pone.0292282.ref001","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"LA Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"pone.0292282.ref002","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092230","article-title":"Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study","volume":"14","author":"J Huang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"B","key":"pone.0292282.ref003","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3889\/oamjms.2022.8296","article-title":"Overall Survival and Related Factors of Advanced-stage Epithelial Ovarian Cancer Patients Underwent Debulking Surgery in Jakarta, Indonesia: A Single-center Experience","volume":"10","author":"H Winarto","year":"2022","journal-title":"Open Access Macedonian Journal of Medical Sciences"},{"issue":"1","key":"pone.0292282.ref004","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13048-019-0503-7","article-title":"Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review","volume":"12","author":"V Dochez","year":"2019","journal-title":"Journal of Ovarian Research"},{"issue":"1","key":"pone.0292282.ref005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/IGC.0000000000000586","article-title":"Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers","volume":"26","author":"G S\u00f6l\u00e9tormos","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"pone.0292282.ref006","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12957-018-1339-0","article-title":"Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index","volume":"16","author":"A Llueca","year":"2018","journal-title":"World J Surg Oncol"},{"issue":"12","key":"pone.0292282.ref007","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123730","article-title":"CA125 and Ovarian Cancer: A Comprehensive Review","volume":"12","author":"P Charkhchi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0292282.ref008","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1038\/s41598-020-59009-z","article-title":"Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer","volume":"10","author":"NC Kampan","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"pone.0292282.ref009","doi-asserted-by":"crossref","first-page":"e0218621","DOI":"10.1371\/journal.pone.0218621","article-title":"Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer","volume":"14","author":"D Furrer","year":"2019","journal-title":"PLOS ONE"},{"issue":"Suppl 2","key":"pone.0292282.ref010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ijgo.12614","article-title":"Cancer of the ovary, fallopian tube, and peritoneum","volume":"143","author":"JS Berek","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"pone.0292282.ref011","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.21037\/gs-2019-ursoc-08","article-title":"Prediction of optimal debulking surgery in ovarian cancer","volume":"10","author":"YJ Song","year":"2021","journal-title":"Gland Surg"},{"issue":"12","key":"pone.0292282.ref012","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11121335","article-title":"Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis","volume":"11","author":"H Amer","year":"2021","journal-title":"J Pers Med"},{"key":"pone.0292282.ref013","doi-asserted-by":"crossref","first-page":"151","DOI":"10.33371\/ijoc.v11i4.533","article-title":"Peran Serum IL-6 dan CA-125 Prabedah sebagai Prediktor Resektabilitas Tumor pada Kanker Ovarium Tipe Epitel","volume":"11","author":"AL Kurniadi","year":"2018","journal-title":"Indonesian Journal of Cancer"},{"issue":"1","key":"pone.0292282.ref014","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13048-020-0614-1","article-title":"Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study","volume":"13","author":"LY Feng","year":"2020","journal-title":"J Ovarian Res"},{"issue":"36","key":"pone.0292282.ref015","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.2174\/0929867324666170712160621","article-title":"Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities","volume":"25","author":"NC Kampan","year":"2018","journal-title":"Curr Med Chem"},{"issue":"1","key":"pone.0292282.ref016","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"X Hu","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"pone.0292282.ref017","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.2147\/CMAR.S179189","article-title":"IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis","volume":"10","author":"L Browning","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"22","key":"pone.0292282.ref018","doi-asserted-by":"crossref","DOI":"10.3390\/cells11223698","article-title":"The Role of IL-6 in Cancer Cell Invasiveness and Metastasis\u2014Overview and Therapeutic Opportunities","volume":"11","author":"M Ra\u0161kov\u00e1","year":"2022","journal-title":"Cells"},{"key":"pone.0292282.ref019","doi-asserted-by":"crossref","DOI":"10.1177\/09636897211027819","article-title":"Metformin antagonizes ovarian cancer cells malignancy through MSLN mediated IL-6\/STAT3 signaling","volume":"30","author":"X Yang","year":"2021","journal-title":"Cell Transplantation"},{"issue":"1","key":"pone.0292282.ref020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ijc.33408","article-title":"Tumor-associated macrophage-targeted therapeutics in ovarian cancer","volume":"149","author":"Y An","year":"2021","journal-title":"International Journal of Cancer"},{"issue":"8","key":"pone.0292282.ref021","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10080251","article-title":"The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer","volume":"10","author":"SS Savant","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"3","key":"pone.0292282.ref022","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ygyno.2012.11.040","article-title":"Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?","volume":"128","author":"R Angioli","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"1","key":"pone.0292282.ref023","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jso.21398","article-title":"Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis","volume":"101","author":"S Kang","year":"2010","journal-title":"J Surg Oncol"},{"issue":"9","key":"pone.0292282.ref024","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/cancers10090277","article-title":"The impact of mesothelin in the ovarian cancer tumor microenvironment","volume":"10","author":"TS Hilliard","year":"2018","journal-title":"Cancers"},{"issue":"4","key":"pone.0292282.ref025","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s12253-020-00823-1","article-title":"Co-expression of mesothelin and CA125 is associated with the poor prognosis of endometrial serous carcinoma and mixed carcinomas including serous carcinoma","volume":"26","author":"S Kakimoto","year":"2020","journal-title":"Pathology & Oncology Research"},{"issue":"3","key":"pone.0292282.ref026","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2478\/raon-2021-0013","article-title":"Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer","volume":"55","author":"S Merlo","year":"2021","journal-title":"Radiology and Oncology"},{"key":"pone.0292282.ref027","doi-asserted-by":"crossref","first-page":"145","DOI":"10.24293\/ijcpml.v25i2.1380","article-title":"Diagnostic value of CA-125 in patients with epithelial ovarian cancer at the DR. Soetomo General Hospital Surabaya in 2016","volume":"25","author":"K Putri","year":"2019","journal-title":"Indonesian Journal of Clinical Pathology and Medical Laboratory"},{"issue":"4","key":"pone.0292282.ref028","doi-asserted-by":"crossref","first-page":"358.e1","DOI":"10.1016\/j.ajog.2011.05.017","article-title":"Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women","volume":"205","author":"K Holcomb","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"pone.0292282.ref029","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s13277-012-0471-7","article-title":"Does HE4 have a role as biomarker in the recurrence of ovarian cancer?","volume":"33","author":"F Plotti","year":"2012","journal-title":"Tumour Biol"},{"key":"pone.0292282.ref030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cca.2014.11.013","article-title":"Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses","volume":"440","author":"X Chen","year":"2015","journal-title":"Clin Chim Acta"},{"issue":"11","key":"pone.0292282.ref031","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1007\/s13277-016-5335-0","article-title":"Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer","volume":"37","author":"Y Shen","year":"2016","journal-title":"Tumour Biol"},{"issue":"1","key":"pone.0292282.ref032","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"RG Moore","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"3","key":"pone.0292282.ref033","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ygyno.2009.10.073","article-title":"The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study","volume":"116","author":"JK Chan","year":"2010","journal-title":"Gynecol Oncol"},{"key":"pone.0292282.ref034","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ejogrb.2020.07.015","article-title":"Meta-analysis of the diagnostic accuracy of HE4 for endometrial carcinoma","volume":"252","author":"J Liu","year":"2020","journal-title":"European Journal of Obstetrics & Gynecology and Reproductive Biology"},{"issue":"1","key":"pone.0292282.ref035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3892\/or.2014.3549","article-title":"Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells","volume":"33","author":"H Wang","year":"2015","journal-title":"Oncol Rep"},{"issue":"5","key":"pone.0292282.ref036","first-page":"1319","article-title":"Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer","volume":"19","author":"M Arab","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"pone.0292282.ref037","first-page":"Cd006014","article-title":"Interval debulking surgery for advanced epithelial ovarian cancer","volume":"2016","author":"S Tangjitgamol","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0292282.ref038","doi-asserted-by":"crossref","first-page":"103209","DOI":"10.1016\/j.critrevonc.2020.103209","article-title":"Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine","volume":"158","author":"JA Perez-Fidalgo","year":"2021","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"pone.0292282.ref039","article-title":"PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian Cancer","author":"A Giannini","year":"2023","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"pone.0292282.ref040","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ygyno.2020.05.681","article-title":"Immunotherapy for platinum-resistant ovarian cancer","volume":"158","author":"G Bogani","year":"2020","journal-title":"Gynecol Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0292282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T17:33:54Z","timestamp":1696440834000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0292282"}},"subtitle":[],"editor":[{"given":"Andrea","family":"Giannini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0292282","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,4]]}}}